Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NMRA
NEUMORA THERAPEUTICS, INC. COMMON STOCK
NASDAQ
$1.39
▼ DOWN 6.08% (-0.09)

KEY STATISTICS

Market Cap$257.55 M
52w High$3.65
52w Low$0.83
Dividend Yield—
Frequency—
P/E-1.13
Volume694.55K
Shares Out.185.28M

COMPANY

LEADERSHIP

Josh Pinto
CHIEF EXECUTIVE
Josh Pinto

COMPENSATION 2026

Salary$700,000
Stock Awards$0
Incentive Plan Pay$504,000
All Other Comp.$11,280
Total$4,562,461

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 15, 2023
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
63

PRICE TARGET

Target High$5.00
Target Low$4.00
Target Median$4.50
Target Consensus$4.50

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

PRICE

$1.39 ▼ DOWN 6.08% (−$0.09)
$1.40$1.44$1.48$1.529:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.39

About Neumora Therapeutics, Inc. Common Stock

https://www.neumoratx.com ↗

Neumora Therapeutics is a clinical-stage biopharma developing treatments for brain, neuropsychiatric, and neurodegenerative diseases, with several candidates in Phase 1-3 trials targeting conditions like depression, dementia, schizophrenia, and Pa...

INDUSTRY

Biotechnology

A PRODUCT NEUMORA THERAPEUTICS, INC. COMMON STOCK IS KNOWN FOR

navacaprant (NMRA-140)
navacaprant (NMRA-140)

A clinical-stage, once-daily oral KOR antagonist in Phase 3 trials, developing a novel treatment for Major Depressive Disorder with a new mechanism of action.

COMPETITORS

COMPETITOR
ALKS COMPARE
ATAI COMPARE
AXSM COMPARE
RLMD COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
62
LISTED HERE
11
RANKED BY POSITION SIZE
VTI
0.00% · 3.4M
IWM
0.00% · 2.5M
SCHA
0.00% · 476.7K
DFAS
0.00% · 221.1K
PRFZ
0.01% · 176.9K
GSSC
0.02% · 139.2K
XRSU.L
0.00% · 93.9K
R2SC.L
0.00% · 76.4K
RSSL
0.01% · 48.7K
BIB
0.01% · 6.6K
AVTM
0.00% · 1.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
28.35%
HOLDERS
141
TOP 12 OF 141 · RANKED BY POSITION SIZE
Siren, L.L.C.
8.5M sh · $16.57M
Softbank Group Corp.
6.5M sh · $11.9M
Perceptive Advisors LLC
5.1M sh · $9.95M
Blackrock Inc.
4.6M sh · $45.25M
Vanguard Group Inc
4.5M sh · $8.13M
Mic Capital Management Uk Llp
4.5M sh · $8.7M
Point72 Asset Management, L.P.
3.7M sh · $6.58M
Millennium Management LLC
3.6M sh · $6.47M
Fmr LLC
3.5M sh · $6.37M
Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust
3.3M sh · $6.45M
Iconiq Capital, LLC
2.6M sh · $4.66M
Lunate Holding Rsc Ltd
2.1M sh · $22.52M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: SEE REMARKS
Aurora Daljit Singh
Sale · 20.6K shares
2026-08-21
★
DIRECTOR, OFFICER: SEE REMARKS
BERNS PAUL L
Purchase · 500.0K shares
2026-08-20
★
OFFICER: SEE REMARKS
Duncan Jason
Purchase · 375.0K shares
2026-08-20
★
OFFICER: SEE REMARKS
Aurora Daljit Singh
Purchase · 200.0K shares
2026-08-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 3
BUY 3
HOLD 1
UNDERWEIGHT 1
8 GRADES IN THE LAST 12 MONTHS
RBC Capital OUTPERFORM Mizuho OUTPERFORM Needham BUY HC Wainwright & Co. BUY Guggenheim BUY William Blair OUTPERFORM Stifel HOLD JP Morgan UNDERWEIGHT

SECTORS PEERS

PEERPRICE
ALMS$22.38COMPARE
OMER$18.61COMPARE
LXRX$2.29COMPARE
FDMT$14.67COMPARE
AUTL$2.34COMPARE
PRTA$9.33COMPARE
FULC$3.85COMPARE
BCYC$4.20COMPARE